California-based Digital twin company for metabolic health Twin Health has secured $53 million in a Series E funding round led by Maj Invest of Denmark, boosting its valuation to $950 million.
WHAT IT DOES
Twin Health offers an AI-enabled digital twin that aims to provide individualized nutrition, sleep and activity guidance by analyzing data from smart devices to help people prevent and reverse metabolic diseases like Type 2 diabetes and obesity.
The company partners with employers and health plans. It will use the funds to accelerate its expansion among health plans and with clients in retail, financial services, manufacturing, technology and healthcare.
"We address the root causes of chronic metabolic diseases to improve and reverse diabetes. Members use their own biomarker data — not population averages — to create their own AI digital twin that guides them in a way that is engaging, precise and sustainable," Jahangir Mohammed, founder and CEO of Twin Health, said in a statement.
"We believe metabolic health is a continuous condition, not an episodic event, and Twin delivers continuous, 24/7 guidance to meet that reality. We envision a future where everyone has an AI digital twin to improve their health and reduce healthcare spend."
MARKET SNAPSHOT
In 2023, the digital metabolic care startup announced it raised $50 million in funding, two years after securing $140 million in Series C funding.
Other companies in the digital twin market include Denmark-based Teton, which offers an AI companion to help nurses monitor patients and optimize workflow.
In May, the company announced it created a real-time live 3D reconstruction of a hospital room using Gefion, Denmark's national supercomputer, with the aim of helping nurses recognize risks early, reduce paperwork and improve patient care.
Another company in the space is Unlearn, which uses machine learning to create digital twins of clinical trial participants before being randomized in a controlled trial.
The digital twin can provide researchers with insight into the participants' health outcomes. The startup pitches its technology as a way to run smaller clinical trials more quickly, since researchers can find fewer participants for the control group.
Last year, Unlearn secured $50 million in Series C funding, bringing its total raise to more than $130 million.
In 2022, the company garnered $50 million in a Series B financing round, two years after scoring $15 million in Series A funding.
